Dan Calkins said he's been feeling everything but secure after he and his wife were shown an error made by the SSA back in 2018 — which they were told to pay for.
Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023Presented Additional Patient Subgroup Data for the.
Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in H1 2024
Expects to Begin Enrollment in Phase 3 Confirmatory.
By Ben Glickman Verastem Oncology named Dan Calkins as its next chief financial officer. The Boston-based biopharmaceutical company said on Thursday that.
Mike Crowther Appointed Chief Commercial and Business Strategy Officer
David Mitchell Appointed Senior Vice President, Head of Regulatory Affairs
Dan Calkins Promoted to Chief Financial Officer.